Adjuvanticity of a CTLA-4 3′ UTR complementary oligonucleotide for emulsion formulated recombinant subunit and inactivated vaccines

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text

Medicine, Clinical Sciences, Oncology +12

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Matthew F. Krummel, James P. Allison · The Journal of Experimental Medicine · 1995 · 2.2K citations · Full text

Life Sciences, Cell Biology, Immunology +17

CTLA-4 can function as a negative regulator of T cell activation

Theresa L. Walunas, Deborah J. Lenschow, Christina Y. Bakker et al. · Immunity · 1994 · 2.2K citations

Life Sciences, Immunology, Molecular Biology +14

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

Omar Qureshi, Yong Zheng, Kyoko Nakamura et al. · Science · 2011 · 1.8K citations · Full text

Life Sciences, Cell Biology, Immunology +17

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

Andrea van Elsas, Arthur A. Hurwitz, James P. Allison · The Journal of Experimental Medicine · 1999 · 1K citations · Full text

Medicine, Immunology, Oncology +17